A highly potent and selective inhibitor Roxyl-WL targeting IDO1 promotes immune response against melanoma

References

• Leklem JE. Quantitative aspects of tryptophan metabolism in humans and other species: a review. Am J Clin Nutr 1971;24:659–72.
   PubMed Web of Science ®Google Scholar
• Ivanova VD. Disorders of tryptophan metabolism in leukaemia. Acta Unio Int Contra Cancrum 1964;20:1085–6.
   PubMedGoogle Scholar
• Wolf H, Madsen PO, Price JM. Studies on the metabolism of tryptophan in patients with benign prostatic hypertrophy or cancer of the prostate. J Urol 1968;100:537–43.
   PubMed Web of Science ®Google Scholar
• Rose DP. Tryptophan metabolism in carcinoma of the breast. Lancet 1967;1:239–41.
   PubMed Web of Science ®Google Scholar
• Bauer TM, Jiga LP, Chuang JJ, et al. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int 2005;18:95–100.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006;213:131–45.
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269–74.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Heikkila PS, Vaara AT, et al. Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer 2009; 9:231.
   PubMed Web of Science ®Google Scholar
• Kallberg E, Wikstrom P, Bergh A, et al. Indoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer model. Prostate 2010;70:1461–70.
   PubMed Web of Science ®Google Scholar
• Astigiano S, Morandi B, Costa R, et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 2005;7:390–6.
   PubMed Web of Science ®Google Scholar
• Ferdinande L, Decaestecker C, Verset L, et al. Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer 2012;106:141–7.
   PubMed Web of Science ®Google Scholar
• Brody JR, Costantino CL, Berger AC, et al. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 2009;8:1930–4.
   PubMed Web of Science ®Google Scholar
• Liu X, Shin N, Koblish HK, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010;115:3520–30.
   PubMed Web of Science ®Google Scholar
• Yue EW, Douty B, Wayland B, et al. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. Open J Med Chem 2009;52:7364–7.
   Google Scholar
• Koblish HK, Hansbury MJ, Bowman KJ, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther 2010;9:489–98.
   PubMed Web of Science ®Google Scholar
• Meng X, Du G, Ye L, et al. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model. Int J Immunopathol Pharmacol 2017;30:215–26.
   PubMed Web of Science ®Google Scholar
• Sun JJ, Chen YC, Huang YX, et al. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier. Acta Pharmacol Sin 2017;38:823–34.
   PubMed Web of Science ®Google Scholar
• Combs AP, Yue EW, Sparks RB, et al. 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase. US8088803, USA; 2012.
   Google Scholar
• Mautino MR, Jaipuri FA, Waldo J, et al. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. Proceedings of AACR 104th annual meeting; 2013 Apr 6–10; Washington, DC.
   Google Scholar
• Guo Q, Yu C, Zhang C, et al. Highly selective, potent and oral mTOR inhibitor for treatment of cancer as autophagy inducer. J Med Chem 2018;61:881–904.
   PubMed Web of Science ®Google Scholar
• Yang S, Li X, Hu F, et al. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. Open J Med Chem 2013;56:8321–31.
   Google Scholar
• Guo C, Chen Y, Gao W, et al. Liposomal nanoparticles carrying anti-IL6R antibody to the tumour microenvironment inhibit metastasis in two molecular subtypes of breast cancer mouse models. Theranostics 2017;7:775–88.
   PubMed Web of Science ®Google Scholar
• Bissantz C, Folkers G, Rognan D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. Open J Med Chem 2000;43:4759–67.
   Google Scholar
• Yamagishi ME, Martins NF, Neshich G, et al. A fast surface-matching procedure for protein-ligand docking. J Mol Model 2006;12:965–72.
   PubMed Web of Science ®Google Scholar
• Yang SY. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 2010;15:444–50.
   PubMed Web of Science ®Google Scholar
• Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. Open J Med Chem 2010;53:2719–40.
   Google Scholar
• Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006;176:6752–61.
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295–307.
   PubMed Web of Science ®Google Scholar
• Pallotta MT, Orabona C, Volpi C, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 2011;12:870–8.
   PubMed Web of Science ®Google Scholar
• Agaugue S, Perrin-Cocon L, Coutant F, et al. 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J Immunol 2006;177:2061–71.
   PubMed Web of Science ®Google Scholar
• Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792–801.
   PubMed Web of Science ®Google Scholar